TNX-650: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (no changed fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia |
No edit summary |
||
| Line 50: | Line 50: | ||
{{DEFAULTSORT:Tnx-650}} |
{{DEFAULTSORT:Tnx-650}} |
||
[[Category:Unnamed monoclonal antibodies]] |
|||
Revision as of 21:47, 6 September 2011
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | IL-13 |
| Clinical data | |
| ATC code |
|
| (verify) | |
TNX-650 is a medication for refractory Hodgkin's lymphoma under development by Tanox. As of December 2009[update], a phase 1/2 clinical trial is recruiting participants.[1]
It is a monoclonal antibody which blocks interleukin 13.[2][3]
References
- ^ Clinical trial number NCT00441818 for "Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma" at ClinicalTrials.gov
- ^ "First Patient Dosed In Phase 1 Trial Of Tanox, Inc.'s TNX-650 - News, Search Jobs, Events". Retrieved 8 July 2008.
- ^ "anti-IL-13 humanized monoclonal antibody TNX-650". NCI Drug Dictionary. National Cancer Institute. Retrieved 10 December 2009.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |